US28036F1057 - Common Stock
EDGEWISE THERAPEUTICS INC
NASDAQ:EWTX (5/6/2024, 10:50:00 AM)
19.395
-0.12 (-0.64%)
Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Boulder, Colorado and currently employs 80 full-time employees. The company went IPO on 2021-03-26. The firm is focused on the discovery, development and commercialization of treatments for severe, rare neuromuscular and cardiac disorders. The company has built its muscle-focused drug discovery platform. Its platform measures integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue. The Company’s lead candidate, EDG-5506, is an investigational orally administered small molecule designed to protect injury-susceptible fast skeletal muscle fibers in dystrophinopathies. EDG-5506 is advancing in multiple clinical trials in individuals with Duchenne, Becker and Limb Girdle 2i muscular dystrophies, and McArdles disease. The firm is also advancing EDG-7500, which is a sarcomere modulator for hypertrophic cardiomyopathy, into IND-enabling preclinical development.
EDGEWISE THERAPEUTICS INC
1715 38Th St
Boulder COLORADO 80303
P: 17202627002
CEO: Kevin Koch
Employees: 80
Website: https://edgewisetx.com/
Here you can normally see the latest stock twits on EWTX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: